This study highlights that ATP6AP1 plays a key role in promoting the lysosomal acidisis-pyroptosis-immunosuppression axis, and targeting ATP6AP1 can reshape the TME and enhance the efficacy of immunotherapy in HCC patients. The gene discussed is ATP6AP1; the disease is hepatocellular carcinoma.